Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
Levi S, Bronstein Y, Goldschmidt N, Morabito F, Ziv-Baran T, Del Poeta G, Bairey O, Del Principe MI, Fineman R, Mauro FR, Gutwein O, Reda G, Ruchlemer R, Sportoletti P, Laurenti L, Shvidel L, Coscia M, Tadmor T, Varettoni M, Aviv A, Murru R, Braester A, Chiarenza A, Visentin A, Pietrasanta D, Loseto G, Zucchetto A, Bomben R, Olivieri J, Neri A, Rossi D, Gaidano G, Trentin L, Foà R, Cuneo A, Perry C, Gattei V, Gentile M, Herishanu Y. Levi S, et al. Among authors: braester a. Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25. Am J Hematol. 2023. PMID: 36349541 Free article. No abstract available.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
Outcomes of Fedratinib in Routine Treatment of Ruxolitinib-Resistant or -Refractory Patients with Primary and Post-Polycythemia Vera or Essential Thrombocythemia Myelofibrosis: A Nationwide Retrospective Study.
Duek A, Tzinman A, Maziuk K, Levy A, Ellis M, Stemer G, Shacham Abulafia A, Cohen A, Lavi N, Ronson A, Braester A, Shapira S, Canaani J, Volchek Y, Leiba R, Leiba M. Duek A, et al. Among authors: braester a. Acta Haematol. 2024 Sep 12:1-7. doi: 10.1159/000540906. Online ahead of print. Acta Haematol. 2024. PMID: 39265539
The Effect of Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes: A Study by the Israeli MDS Working Group.
Merkel D, Soffer S, Filanovsky K, Braester A, Fibach E, Dana M, Ofran Y, Greenbaum U, Nagler A, Amitai I, Mittelman M. Merkel D, et al. Among authors: braester a. Acta Haematol. 2024;147(4):427-434. doi: 10.1159/000535749. Epub 2023 Dec 16. Acta Haematol. 2024. PMID: 38104534 Free PMC article. Clinical Trial.
COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding.
Demelo-Rodriguez P, Alonso-Beato R, Jara-Palomares L, Galeano-Valle F, Bura-Riviere A, Visonà A, Francisco I, Vidal G, López-Ruiz A, Monreal M; RIETE Investigators. Demelo-Rodriguez P, et al. Res Pract Thromb Haemost. 2023 Sep 20;7(7):102206. doi: 10.1016/j.rpth.2023.102206. eCollection 2023 Oct. Res Pract Thromb Haemost. 2023. PMID: 37840687 Free PMC article.
152 results